Swedish Orphan Biovitrum AB (publ) (Sobi) announces its results for the fourth quarter and full year of 2021.
October - December 2021
Total revenue SEK 4,896 M (4,581), +7 per cent, +9 per cent at constant exchange rates (CER)
Haematology revenue SEK 2,242 M (2,081), +8 per cent at CER of which Elocta SEK 1,063 M (1,071), unchanged at CER, Alprolix SEK 482 M (419), +16 per cent at CER, and Doptelet SEK 306 M (191), +60 per cent at CER. First shipment of Empaveli achieved
Immunology revenue SEK 2,330 M (2,281), +6 per cent at CER of which Kineret SEK 682 M (586), +16 per cent at CER, Synagis SEK 1,364 M (1,432), +1 per cent at CER, and Gamifant SEK 284 M (263), +10 per cent at CER
EBITA1 SEK 2,002 M (2,576), EBITA margin1 41 per cent (56, adjusted 48)
Earnings per share (EPS) before dilution SEK 4.21 (5.09)
Cash flow from operating activities SEK 2,121 M (716)
Aspaveli EU approval and Kineret EU approval extension
January - December 2021
Total revenue SEK 15,529 M (15,261), +2 per cent, +7 per cent at CER
Haematology revenue SEK 8,536 M (8,660), +3 per cent at CER of which Elocta SEK 3,960 M (4,585), -11 per cent at CER, Alprolix SEK 1,764 M (1,705), +7 per cent at CER, and Doptelet SEK 1,116 M (587), +104 per cent at CER
Immunology revenue SEK 5,780 M (5,415), +15 per cent at CER of which Kineret SEK 2,290 M (2,079), +16 per cent at CER, Synagis SEK 2,650 M (2,726), +6 per cent at CER, and Gamifant SEK 840 M (609), +48 per cent at CER
EBITA1 SEK 5,575 M (6,700), EBITA margin1 36 per cent (44, adjusted 41)
EPS before dilution SEK 9.08 (11.01)
Cash flow from operating activities SEK 5,470 M (4,926)
2022 outlook
Revenue is anticipated to grow by a mid to high single-digit percentage at CER
EBITA margin is anticipated to be at a low 30s percentage of revenue
Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session at 12:00 CET. The event will in English.
The presentation can be followed live or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please call:
Sweden: +46 8 505 583 73 (direct)
UK: +44 3 333 009 272 (direct)
US: +1 631 913 14 22 (toll) PIN: 50558397#
Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.
This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 10 February 2022.
Contact:
Thomas Kudsk Larsen
Head of Communication and Investor Relations
Maria Kruse
Director of Communication and Investor Relations
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm
Sweden
Phone: 46 8 697 20 00
WEB: www.sobi.com